Biopharma company Population Genetics has raised series B funding from backers including agribusiness firm Syngenta.
UK-based biopharmaceutical company Population Genetics secured £3.6m ($5.7) in financing on Tuesday last week from investors including Syngenta Ventures, the corporate venturing division of Switzerland-based agribusiness corporation Syngenta.
In addition to the funding, Population has signed a research agreement with Syngenta’s biotechnology division aimed at finding valid ways to use Population’s technology in plant breeding studies.
Joining Syngenta in the series B round were venture capital (VC) firm Auriga Partners, private equity firm Beringea, medical research foundation The Wellcome Trust,…
